Cannabis compounds tested to fight HIV brain inflammation

NCT ID NCT05514899

Recruiting now Knowledge-focused Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how CBD and THC, two compounds found in cannabis, affect inflammation and brain health in people with HIV. About 90 participants will take both substances in a random order over six weeks. Researchers will measure blood markers and brain function to better understand how cannabis interacts with HIV-related inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cannabidiol (CBD) and tetrahydrocannabinol (THC)
What this could lead to: If successful, this could point toward new ways to reduce inflammation and brain problems in people with HIV.
What could go wrong: This is a small, early-stage study focused on understanding, not treatment. Results may not lead to any new therapies, and cannabis can have side effects like dizziness or mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence HIV infectious disease Neuroinflammatory Diseases neuronitis thrombocytopenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANNABIS HIV MICROBIOME NEUROINFLAMMATORY DISEASE NEUROINFLAMMATORY RESPONSE THC

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

HIV Neurobehavioral Research Program (HNRP)
RECRUITING

San Diego, California, 92103, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.